RITEMVIA

This brand name is authorized in Austria, Cyprus, Estonia, Lithuania, New Zealand, Poland

Active ingredients

The drug RITEMVIA contains one active pharmaceutical ingredient (API):

1 Rituximab
UNII 4F4X42SYQ6 - RITUXIMAB

Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas.

Read about Rituximab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
RITEMVIA Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01FA01 Rituximab L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FA CD20 (Clusters of Differentiation 20) inhibitors
Discover more medicines within L01FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1749797, 1780589
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1083424, 1085386
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 19645, 19646
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100392310, 100417910

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.